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Abstract 
COST EFFECTIVENESS ANALYSIS IN ORTHOPAEDIC SURGERY.  
Husham Sharifi and Mohammad Diab. Department of Orthopaedic Surgery, University of 
California at San Francisco, San Francisco, CA. (Sponsored by Jonathan Grauer, Department of 
Orthopaedic Surgery, Yale University School of Medicine.) 
 
The purpose of this thesis was to explore the use of cost effectiveness for interventions in 
orthopaedics. This was done through three cost effectiveness articles that have been published by 
the author. In each of these articles, similar methodologies were used. Decision models were 
constructed for cost-effectiveness analyses of competing orthopaedic interventions. Outcome 
probabilities and effectiveness values were derived from the literature. Effectiveness was 
expressed in quality adjusted life years gained. Cost data were compiled and verified from either 
hospital cost data or from Medicare data. Costs and utilities were discounted in accord with the 
United States Panel on Cost Effectiveness in Health and Medicine. Principal outcome measures 
were average incremental costs, incremental effectiveness, incremental quality-adjusted life 
years, and, in the case of one article, net health benefits. In particular the articles compared the 
following: 1. Core decompression versus conservative management for osteonecrosis of the hip 
as a way to delay hip replacement; 2. Total knee arthroplasty versus unicompartmental knee 
arthroplasty; and 3. Periacetabular osteotomy versus total hip arthroplasty for a young adult with 
developmental dysplasia of the hip. The more cost effective intervention was identified in each 
case, along with implications of the results for clinical and operative decision-making. Cost 
effectiveness was found to be a useful tool in orthopaedic surgery under limited circumstances of 
either scarce data on new interventions or the need to use more resources to achieve greater 
effectiveness. It also can provide excellent insight into ways to direct future clinical research. 
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Introduction 
The goal of clinical research is identify issues of concern to doctors and answer the questions that 
those issues raise [1]. Randomized trials are the gold standard for providing these answers [2]. 
Unfortunately, randomized trials pose several inherent difficulties to structure, especially in 
orthopaedic surgery. Most surgeries in orthopaedics have outcomes that are durable. They last for 
years without any need for revision. A randomized trial would need to follow patients over an 
extended span of time, which can be logistically complex. The problem becomes even more 
challenging when one tracks a cohort large enough to achieve statistical significance. Even if 
these challenges could be surmounted, they would not provide answers until long into the future. 
Decisions still need to be made in the short and medium term. The expertise that comes from 
experience can be used for interim decisions, and that expertise can be supplemented by decision 
analysis.  
 
The typical use of decision analysis in economic circles has been to assess competing alternatives 
for achieving a common endpoint. Its use in orthopaedic surgery is to quantify variables for 
patient outcome and apply these numbers to a model that adequately represents reality [3-5].  To 
understand how this is the case, one must first have a clear definition of decision analysis. 
Decision Analysis  
The core idea of decision analysis is that resources are finite and that patient benefit must be 
maximized given finite resources. This differs from regular clinical judgment in that the 
information is quantified and the steps of the decision are put into a model. The model usually 
takes the form of a decision tree, with the choice under consideration at the base of the tree. The 
tree is built from left to right by adding successive branches. Each branch is made at a node, and 
each node has an outcome. Outcomes are quantified in a way that represent value for the patient. 
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In its simplest form a decision tree has only one decision to make, that of the first branch. In 
orthopaedic surgery this usually means choosing one surgical technique over another. All 
successive branches are constituted by chance nodes, in which each node is assigned a probability 
of occurring based on the chance of a certain outcome. The chance may be determined by a 
complication rate and a consequently mediocre outcome, by no complications and a consequently 
excellent outcome, by needing a revision, by death, or in fact by any clinically relevant event.   
 
In building such a tree the burden of approximating reality is on the modeler. The outcomes and 
probabilities must come from the best possible evidence. When randomized trials are not 
available, other sources may be suitable. Observational trials constitute such a source, as do 
registries and claims databases. The latter may be especially useful with respect to cost 
calculations. All these must be accessed through a systematic review of the literature. Systematic 
review may already have been done in a database such as the Cochrane database, or it may need 
to be done by the modeler. Inclusion and exclusion criteria should be determined beforehand and 
should be transparent to anyone looking at the model. The goal of the literature review is to find 
clinically relevant outcomes and probabilities. Although a decision tree is formed before the onset 
of reviewing the literature, it should be continuously revised to reflect clinical reality as closely as 
possible. The literature review itself can help iterate and improve the tree.   
 
Just as the exclusion/inclusion criteria should be transparent, the results of the literature review 
should be transparent. In fact they should comprise part of the reported methodology. In the ideal 
case the modeler would present a meta-analysis in which effect size is calculated according to a 
meta-regression. Study characteristics would be statistically controlled when calculating overall 
averages. In reality most decision analysis studies will compile simple means. There will also be 
cases in which the literature does not provide adequate results. This may be especially true for 
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quantified measurements of health outcomes. In such a case one may need to rely on expert 
opinion (i.e., the opinion of an experienced doctor involved in the modeling effort). 
 
The quantification of health outcomes is in fact one of the more difficult tasks in developing a 
decision analysis. One may try to achieve objectivity by measuring an outcome as the absence of 
a well-known complication. In cardiology, for example, this could be the measurement of 
whether ventricular remodeling occurs after a myocardial infarction. The administration of an 
ACE inhibitor reduces the probability of such a complication. The percentage of patients who do 
not have ventricular remodeling would be the outcome. There are many limitations to such an 
approach, a discussion of which is outside the scope of this thesis.  
 
The trend among researchers in the field of decision analysis is to include outcomes that represent 
the value experienced either by the patient directly or by society at large. To be specific, an extra 
year of life in a vigorous state of health may have a higher value for a patient than an extra year 
spent undergoing chemotherapy. That year may also be valued differently by society, which loses 
the benefit of an individual’s contributions and, in some form, incurs the cost of treatment. 
Conventional opinion is that the best way to capture these differences is in the form of quality 
adjusted life years (QALYs) [6-8]. Numerically, QALYs are defined as the extra years of life 
achieved by the patient multiplied by a utility that represents the quality of living during those 
years. The utility is measured on a scale of 0 to 1, with 0 being death and 1 being the highest 
possible quality of life. In most cases these utilities are obtained from the patients themselves, 
using measurement techniques such as time tradeoff and standard gamble [6]. In a minority of 
cases, utilities are determined by a proxy for the patient, such as the doctor [9, 10]. There are 
questionnaires that assess utility, such as EuroQoL and the Short Forms. Additionally, there are 
new methods that translate Short Form 36 and Short Form 12 into utilities that range from 0 to 1 
[11].  
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The next step is to cull the literature for probability rates of possible outcomes. The process for 
doing so is described above, and often the effort of finding appropriate outcomes leads one to 
discover corresponding probabilities and complications. This activity helps to fill in and further 
develop the decision tree. Once all of these data are established and appropriately modeled, one 
can run the tree. It can be run as a Markov model, if the states under consideration are best 
represented as iterations over an extended period of time. Alternatively, it can be run as a static 
decision tree, in which final outcomes – that is, outcomes at the far right of the tree – are 
multiplied by the probability of the branch that leads to them. These are then represented on the 
node that gives rise to the branch. The process is continued with probabilities and branches that 
precede each node. It is repeated until the single decision at the left-most side of the tree is 
reached. That yields a utility of one decision versus another, which in orthopaedics means one 
procedure versus another. 
 
Such a static model is of course restrictive. Even with the most careful literature review and the 
most conscientious model development, one still does not capture even a small fraction of clinical 
reality. Sensitivity analysis offers enough flexibility to address this problem. Input for the model 
is varied along clinically relevant ranges, which is defined both from the literature and from 
expert opinion of doctors in the field. When limited evidence supports a particular variable, the 
range for the sensitivity analysis should be broad. When an abundance of evidence exists, the 
range can be narrow. In all cases the robustness of variables is assessed. Robustness determines 
how much a result depends on a specific variable. A result depends greatly on the value of a 
sensitive variable; it depends very little on the value of a robust variable. Put differently, a small 
change in a sensitive variable produces a large change in the final result. A large change in a 
robust variable produces a small change in the final result. Such an understanding of the model 
comes from one-way, univariate sensitivity analysis – that is, changing one variable at a time and 
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seeing what the consequent model outcome is. Whenever possible, one should also perform 
multivariate sensitivity analysis in which 2 or more variables are changed simultaneously and 
consequent model outcome is assessed. Even for weak models, this activity allows doctors to use 
results in a way that is much more likely to reflect the reality they face from day to day. 
 
The entire process that has been described is in fact not cost effectiveness analysis. (See 
Appendix A for the distinction between cost effectiveness and cost utility.) It does not include 
cost. The inclusion of cost may appear simple at face value; in reality it poses tremendous 
challenges. First, one must decide whether they use readily available charge data, such as is 
published in Medicare diagnostic related groups (DRGs). These rarely reflect the actual 
expenditure to the care provider, and the difference can be either an underestimate or an 
overestimate. More accurate estimations often require permission to review hospital financial data 
and are more difficult to access. Fortunately, the accounting software of the hospital’s financial 
department does an adequate job of assessing the resources used by an institution for a given 
procedure.  
 
The other challenge is the perspective from which cost is calculated. The cost incurred by the 
individual is different than the cost incurred by the health care system. Premium-based insurance 
plans in fact create incentives for direct conflict between these two. Furthermore, the cost 
incurred by society is a third cost altogether. One way to grapple with the issue is to separate 
direct costs and indirect costs. Direct costs includes goods, services, and other resources that were 
consumed in the provision of care. Indirect costs include issues such as opportunity costs, which 
measure what cost an individual incurs when losing one opportunity in order to benefit from 
another opportunity. For example, a woman who misses several days of work to undergo a 
procedure benefits from the procedure but loses some amount of wage earnings. Another example 
of an indirect cost is when a spouse must spend time taking care of a patient in the post-operative 
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period instead of participating in other activities. In essence indirect costs capture the idea of cost 
from the perspective of society. For this reason they are favored by practitioners of cost 
effectiveness.  
 
The assessment of indirect costs can be daunting. There is admittedly no satisfying solution, as of 
the writing of this thesis, to the challenge. It appears to be a common problem in the world of 
modeling outside of medicine as well, which suggests that it may be inherent to the methodology 
of decision analysis. Some physicians suggest that the calculations produced by hospital 
accounting software serve as adequate proxies for cost from a societal perspective, which 
includes indirect costs [6, 7]. 
 
The final step in the inclusion of cost is to ensure that monetary values accurately reflect the 
value of money in the present day. In the world of finance, there is enough liquidity and 
transparency in currency exchange that we can roughly assess the value of a currency with 
respect to goods and other currencies. This results in historical records of the changing value of 
money, which in the US has been a rate of inflation of 2-5% for the last 25 years. When data on 
outcomes are gathered, they must be discounted by a percentage rate that takes into account the 
real devaluation of our currency. The model can then use cost data expressed in current dollar 
values. The same requirement applies to projections into the future. Convention dictates that both 
costs and utilities should be discounted at approximately 5% [6, 7]. 
 
Decision analysis in orthopaedic surgery 
Orthopaedic surgery as a field can benefit from decision analysis as it is described above. The 
following 3 articles illustrate the use of cost effectiveness analysis, with the application of the 
principles that have been laid out. These articles are the product of research conducted and 
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published by the author of this thesis. The first article analyzes the cost effectiveness of core 
decompression of a hip with osteonecrosis as a way to delay hip replacement. The second article 
analyzes the cost effectiveness of total knee arthroplasty versus unicompartmental knee 
arthroplasty. The third article analyzes the cost effectiveness of periacetabular osteotomy versus 
total hip arthroplasty in the treatment of the young adult with developmental dysplasia of the hip.  
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Methods 
Cost-effectiveness Analysis of Core Decompression 
General Framing and Design 
This cost-effectiveness analysis follows the methodological guidelines of the Panel on Cost 
effectiveness in Health and Medicine convened by the US Public Health Service in 1993[6]. The 
panel outlined an explicit set of recommendations in a reference case analysis. These reference 
case guidelines established a common set of standards to improve the comparability of cost-
effectiveness analyses. Issues addressed in the reference case analysis include standard practices 
for framing and perspective of the study, identification of outcomes, estimation of costs, and 
testing of uncertainty [6]. This study was constructed adhering to these standards.  
 
Consistent with the reference case guidelines, this analysis compares the cost-effectiveness of 
core decompression to the commonly accepted treatment alternative of observation in the early 
stages of osteonecrosis. This analysis assumes a target patient population seeking treatment of 
femoral osteonecrosis at the age of 40 years. The time horizon of this analysis encompasses the 
remaining life expectancy for this target population.  
 
The cost effectiveness ratios for observation and core decompression were analyzed from the 
societal perspective. The boundary of the analysis is limited to the costs and health effects 
directly impacting the target population. Estimates of costs, effectiveness, and the probability of 
various outcomes were obtained from literature review.  
 
Literature Review 
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Literature review was used to construct the event pathways following observation and core 
decompression. A literature search identified 269 articles between 1978 and 2004 using the 
keywords osteonecrosis, decompression, hip, and outcome. Seventy- eight articles were identified 
as relevant to the treatment of osteonecrosis with either core decompression or observation. 
Fifteen publications were review articles and excluded from further analysis. The remaining 
articles were assessed on their quality. We excluded articles with fewer than 50 subjects. 
Additional criteria used to select articles included adequate reporting of magnetic resonance 
imaging staging and standardized surgical technique. A total of 11 studies were identified and 
selected for abstraction using these criteria. A summary of the abstracted data are included in 
Appendix B. 
 
Decision Model 
Decision tree software (TreeAge Pro; TreeAge Software Inc, Williamston, Mass) was used to 
create a model for the treatment of femoral head osteonecrosis [8, 12-17]. A simplified schematic 
of the decision tree is shown in Figure 1. The model begins with the decision for either 
observation or core decompression. Literature review was used to identify possible outcomes and 
their probability after each of these treatment alternatives. These event pathways were 
incorporated as branches in the decision tree. This model assumed a target population of patients 
seeking treatment of osteonecrosis at the age of 40 years. This age is consistent with the typical 
age at which core decompression is performed for osteonecrosis of the hip [18]. The time horizon 
of the model follows events through the remaining life expectancy of 39 years for this age group 
[19]. The event pathway for observation follows the clinical course of patients with early 
osteonecrosis and assumes that they become symptomatic and require THA after a 2-year period. 
This period is consistent with the natural history of osteonecrosis [18, 20, 21].  
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QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
 
Figure 1: Simplified schematic of decision model for the treatment of femoral head osteonecrosis 
 
The event pathways following core decompression were constructed following literature review. 
There has been a wide range of results reported on the efficacy of core decompression [22-30]. A 
reference case was created and assumed a period of 10 years before the need for primary hip 
arthroplasty after core decompression compared with 2 years with observation. This assumption 
is consistent with the more favorable reports of the results of core decompression. The efficacy of 
core decompression in delaying hip arthroplasty for this duration has not been definitively 
established in the published literature. Given this uncertainty, the effects on the cost-effectiveness 
of core decompression of both shorter and longer assumptions for its efficacy are examined in the 
sensitivity analysis. The primary complication included in the model following core 
decompression is subtrochanteric hip fracture requiring operative intervention. This complication 
has been infrequently reported, but rates as high as 5% have been published [22-30]. An 
intermediate value of 2% was selected for the reference case, and sensitivity analysis was used to 
examine the effect of rates in the range of 0% to 5%.  
 
Subsequent events after observation and core decompression are modeled to include the potential 
need for hip arthroplasty and revisions over the lifetimes of the target population. Complications 
after hip arthroplasty include dislocation, infection, and death [31]. The decision model 
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incorporates the need for subsequent hip revision surgery and the possible complications that can 
arise. The incidence of complications is assumed to increase with subsequent revision procedures, 
whereas the durability of revision arthroplasty is assumed to decrease relative to primary 
arthroplasty [32-34]. The probabilities of infection, dislocation, and mortality used in this model 
are shown in Table 1. The rates of these complications were selected to fall in the midrange of 
estimates reported in the literature. Most studies have reported rates of infection leading to 
implant failure near the value of 1% used in the reference case of this study [32, 33, 35, 36]. 
Mortality and dislocation rates have not been as definitively established. The reference case of 
0.5% for mortality is consistent with the low rates generally reported [37]. The dislocation rate of 
2.5% used in the reference case is consistent with reports of large database studies [31, 33]. 
Sensitivity analysis was used to address the uncertainty of these assumptions for complication 
rates by examining the effect of higher and lower rates on the results. 
 
Complication Probability (%) 
Complication rate primary THA 4 
Infection 1 
Dislocation 2.5 
Mortality 0.5 
Complication rate revision THA 10 
Complication rate second or third revision THA 15 
Table 1: Complication Rates Used in Decision Model After THA 
 
Effectiveness 
This study is a special case of cost-effectiveness analysis termed cost-utility analysis. Cost-utility 
analyses are differentiated by the fact that effectiveness is measured in units that incorporate a 
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subjective measure of utility such as quality adjusted life years (QALYs). The treatment of 
osteonecrosis has limited effect on survival but does result in significant changes in the quality of 
life of patients. The use of QALYs to measure effectiveness allows the survival of patients in 
different health states to be corrected for health related quality of life using a utility factor.  
 
Utility factors were assigned to all health states in the model to adjust survival for quality of life. 
The reference case guidelines define utility along a continuum with a factor of 1.0 representing 
perfect health and a factor of 0.0 representing death [6] . Specific utility values for each health 
state in this study were assigned following a literature review. Table 2 lists the health states 
included in the decision model along with their corresponding utility values. Large-scale studies 
have used questionnaires to establish utility values for a variety of health states. Arthritis has 
consistently been shown to have a utility value near 0.7 [11, 38-40]. Knee and hip arthroplasties 
have been shown to increase quality of life weightings close to normal values. Based on these 
studies, this analysis uses a utility value of 0.9 for successful hip arthroplasty. Revision 
arthroplasty is given a lower utility value to reflect the diminished clinical results compared with 
primary arthroplasty. The utility values used for resection arthroplasty and surgical complications 
were also identified in literature review.  
 
Health state Utility value 
Primary THA 0.9 
Treatment of dislocation 0.5 
Treatment of infection 0.5 
Surgery and postoperative recovery 0.5 
Death 0.0 
Successful core decompression 0.9 
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Revision THA 0.85 
Resection hip arthroplasty 0.6 
Table 2: Utility Values for Health States Occurring in Decision Model 
 
The period after successful core decompression was assigned a utility similar to that of successful 
arthroplasty. This reflects the assumption that successful core decompression results in a well-
functioning hip but does not completely restore normal utility. The ability of core decompression 
to control symptoms and maintain a high level of function has not been definitively documented 
in the published literature. To address this uncertainty, sensitivity analysis was used to examine 
the impact of both higher and lower utility values after core decompression on its cost-
effectiveness. 
 
Costs 
Gross-costing methodology was used to estimate the direct lifetime treatment costs after both 
observation and core decompression [6]. This methodology relies on global Medicare charge and 
reimbursement data to approximate the direct costs for various procedures. Indirect costs such as 
lost productivity were not included in this analysis. The surgical interventions occurring in the 
decision model were assigned their appropriate International Classification of Diseases, Ninth 
Revision; diagnosis related groups (DRGs); and Current Procedural Terminology (CPT) codes. 
Gross cost estimates were then determined for short-term care hospitalizations and physician 
services based on charge and reimbursement data for these codes. The cost estimates are shown in 
Table 3.  
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Procedure DRG (cost [$]) 
Core decompression 210 (8086) 
Primary THA 209 (9183) 
Revision THA 209 (9183) 
Resection arthroplasty 210 (8086) 
Reduction of dislocated hip prosthesis 210 (8086) 
Operative treatment of infected hip prosthesis 210 (8086) 
Open reduction and internal fixation of hip fracture 210 (8086) 
Table 3: Costs for DRG and CPT Codes Occurring in Decision Model Using 1998 Medicare 
Data 
 
Gross cost estimates for short-term care hospitalizations were determined from mean hospital 
costs for the DRG associated with each intervention. Mean hospital costs were based on data 
from the Centers for Medicare and Medicaid Services reported for 1998 [41]. These costs are 
derived by applying Medicare cost-to-charge ratios to the data from the MedPAR data source 
[41]. The MedPAR data source is released annually by Medicare and provides cost estimates for 
each DRG. This study used the MedPAR data for 1998 pertaining to all US hospitals [41, 42].  
 
The gross costs for physician services were determined from mean Medicare reimbursement for 
the CPT code associated with each surgical intervention. The mean reimbursement reported by 
the Centers for Medicare and Medicaid Services in 1998 for the Los Angeles, California, carrier 
was used. This global reimbursement includes preoperative care, surgical fees, and 90 days of 
postoperative care [43]. 
 
 19 
Discounting 
Cost-effectiveness analysis requires that all future costs and health consequences be discounted 
and stated in their present-day values. Discounting is performed to correct for the fact that costs 
that are deferred to the future are preferable to immediate expenditures. Costs and health effects 
were discounted in the reference case at a constant rate of 3% annually. Sensitivity analyses were 
conducted with discount rates of 0% and 5% [6, 8]. 
 
Sensitivity Analysis 
Sensitivity analysis was conducted to test the uncertainty of the reference case results. Cost 
effectiveness analysis combines information from several data sources to generate estimates of 
the probability of different outcomes and assign values to their utility and costs. Uncertainty 
about the true values of these underlying parameters results in uncertainty about the cost-
effectiveness ratios generated in the reference case. Sensitivity analysis is used to determine the 
impact of varying the assumed values for key variables on the conclusions generated by the cost-
effectiveness analysis.  
 
Initially, cost effectiveness ratios were calculated using the reference case assumptions for both 
observation and core decompression. Sensitivity analysis was then performed using different 
assumptions for the values of the underlying variables [6]. Several key variables were selected for 
sensitivity analysis. These variables included the delay in hip arthroplasty resulting from core 
decompression, the functional utility after successful core decompression, the incidence of 
complications after core decompression, and the incidence of complications after both primary 
and revision hip arthroplasty. 
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Cost-Effectiveness Analysis of Unicompartmental Knee 
Arthroplasty as an Alternative to Total Knee Arthroplasty for 
Unicompartmental Osteoarthritis 
This cost-effectiveness analysis follows the methodological guidelines of the Panel on Cost-
Effectiveness in Health and Medicine convened by the United States Public Health Service in 
1993[6]. Consistent with these reference case guidelines, the present analysis compares the cost-
effectiveness of unicompartmental arthroplasty with the commonly accepted treatment alternative 
of total knee arthroplasty for unicompartmental arthritis. This analysis assumes a target patient 
population seeking treatment for unicompartmental arthritis at the age of sixty-five years. The 
time horizon of this analysis encompasses the remaining eighteen years of life expectancy for this 
target population [19]. The cost effectiveness ratios for unicompartmental and total knee 
arthroplasty were analyzed from the societal perspective. The boundary of the analysis is limited 
to the costs and health effects directly impacting the target population. Estimates of costs, 
effectiveness, and the probability of various outcomes were obtained from a literature review. 
 
Literature Review 
A literature review was used to construct the event pathways following initial treatment with 
unicompartmental knee arthroplasty and total knee arthroplasty. We identified 345 articles, 
published from 1975 through 2004, using the following keywords: unicompartmental, 
unicondylar, knee arthroplasty, results, outcomes, cost, and effectiveness. We included articles 
published in the years 1994 through 2004 in order to best reflect the results from the current 
clinical use of unicompartmental knee arthroplasty. We excluded studies involving fewer than 
fifty subjects. Additional criteria used to select articles included the selection of patients with an 
intact anterior cruciate ligament and documented unicompartmental disease and the exclusion of 
patients who had a prior patellectomy or tibial osteotomy. A total of nine studies were identified 
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and selected for abstraction with use of these criteria [44-52].  
 
Decision Model 
Decision-tree software (TreeAge Pro; TreeAge Software, Williamstown, Massachusetts) was 
used to create a model for the treatment of unicompartmental arthritis [8, 12-17]. A simplified 
schematic of the decision tree is shown in Figure 2. The model begins with the decision for either 
unicompartmental or total knee arthroplasty. A literature review was used to identify possible 
outcomes and their probability following each of these treatment alternatives.  
 
QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
 
Figure 2: Simplified schematic of the decision model for the treatment of unicompartmental 
arthritis of the knee. TKA = total knee arthroplasty, and UKA = unicompartmental knee 
arthroplasty. 
 
The event pathways following unicompartmental knee arthroplasty and total knee arthroplasty 
were constructed following the literature review. A wide range of results has been reported on the 
effectiveness of unicompartmental knee arthroplasty [44-53]. The reference case assumes a 
period of twelve years for the durability of a unicompartmental arthroplasty. This assumption is 
consistent with results of unicompartmental knee arthroplasty in the nine studies selected for data 
abstraction [44-52]. Sensitivity analysis was used to examine the effects on the cost-effectiveness 
of unicompartmental knee arthroplasty of both shorter and longer assumptions for its durability. 
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Total knee replacement was assumed in the reference case to have a survival of fifteen years. This 
value is longer than the survival assumed for unicompartmental knee replacement and reflects the 
fact that long-term outcomes have been more thoroughly documented for total knee replacement 
[54].  
 
Subsequent events following unicompartmental knee arthroplasty and total knee arthroplasty 
were modeled to include the potential need for revision total knee arthroplasty as well as 
complications over the lifetime of the target population. Complications included infection and 
death[54]. The rates of these complications were selected to fall in the midrange of estimates 
reported in the literature. Most studies have described rates of infection leading to implant failure 
near the value of 1% used in the reference case of this study [54-56]. The reference case of 0.5% 
for mortality is consistent with the low rates generally reported [56]. 
 
Effectiveness 
Utility factors were assigned to all health states in the model to adjust survival for quality of life. 
The reference case guidelines define utility along a continuum with a factor of 1.0 representing 
perfect health and a factor of 0.0 representing death [38]. Specific utility values for each health 
state in this study were assigned following a literature review (Table 4). Arthritis has been shown 
to have a utility value near 0.723 [38]. Knee and hip arthroplasty have been shown to increase 
quality-of-life weightings close to normal values. On the basis of these studies, this analysis uses 
a utility value of 0.9 for successful unicompartmental and total knee arthroplasty [11, 38-40]. 
Revision arthroplasty is given a lower utility value to reflect the diminished clinical results 
compared with primary arthroplasty. Previously published data were used to assign a utility value 
of 0.6 for resection arthroplasty and 0.5 to periods of surgery and postoperative recovery 
following complications [40]. Sensitivity analysis was used to examine the effect of uncertainty 
about the utility values for unicompartmental knee arthroplasty and total knee arthroplasty on the 
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cost-effectiveness results. 
 
Health State Utility Value 
Primary total knee arthroplasty  0.9 
Unicompartmental knee arthroplasty  0.9 
Treatment of infection  0.5 
Surgery and postoperative recovery  0.5 
Death  0.0 
Revision total knee arthroplasty  0.85 
Resection knee arthroplasty 0.6 
Table 4: Utility Values for Health States Occurring in the Reference Case of the Decision Model 
 
Costs 
Gross-costing methodology was used to estimate the direct lifetime treatment costs following 
both unicompartmental and total knee arthroplasty [6]. The surgical interventions occurring in the 
decision model were assigned their appropriate ICD-9 (International Classification of Diseases–
Ninth Revision), DRG (Diagnosis-Related Group), and CPT (Current Procedural Terminology) 
codes. Gross-cost estimates for acute care hospitalizations were determined from mean hospital 
costs for the DRG associated with each intervention. The mean hospital costs were based on data 
from the Centers for Medicare and Medicaid Services reported for 1998 [57]. These costs are 
derived by applying Medicare cost-to-charge ratios to the data from the Medicare Provider 
Analysis and Review File (MEDPAR) data source [57]. The MEDPAR data source is released 
annually by Medicare and provides cost estimates for each DRG [42, 57]. The gross costs for 
physician services were determined from the mean Medicare reimbursement for the CPT code 
associated with each surgical intervention (Table 5) [43]. 
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 DRG CPT 
Procedure Code Cost Code Cost 
Unicompartmental knee arthroplasty  209  $9183  27446  $1445 
Primary total knee arthroplasty  209  $9183  27447  $1951 
Revision total knee arthroplasty  209  $9183  27487  $2298 
Resection arthroplasty  210  $8086  27488  $1348 
Operative treatment of infection around knee prosthesis  
210 
 
$8086 
 
27310 
 
$797 
Table 5: Costs for DRG and CPT Codes in Decision Model with Use of 1998 Medicare data. 
Values are based on 1998 United States dollars. DRG = Diagnosis-Related Group, and CPT = 
Current Procedural Terminology. 
 
Discounting 
Cost-effectiveness analysis requires that all future costs and health consequences be discounted 
and stated in terms of their present-day values. Discounting is performed to correct for the fact 
that costs that are deferred to the future are preferable to immediate expenditures. Costs and 
health effects were discounted in the reference case at a constant rate of 3% annually [6, 8]. 
 
Sensitivity Analysis 
Sensitivity analysis was used to determine the impact of varying the assumed values for key 
variables on the conclusions generated by this cost-effectiveness analysis. Cost effectiveness 
analysis combines information from several data sources in order to generate estimates of the 
probability of different outcomes and to assign values to their utility and costs. Uncertainty about 
the true values of these underlying parameters results in uncertainty about the cost-effectiveness 
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ratios generated in the reference case. Sensitivity analysis was performed with use of different 
assumptions for the values of the underlying variables [6]. Several key variables that were 
selected for sensitivity analysis included the durability of unicompartmental knee replacements 
relative to total knee replacements, the functional utility following unicompartmental 
arthroplasty, and the cost of unicompartmental knee arthroplasty. 
 
Cost-Effectiveness Analysis of Periacetabular Osteotomy 
General Model Overview 
The model and analysis in this study were constructed according to the guidelines set forth by the 
Panel on Cost- Effectiveness in Health and Medicine by the United States Public Health Service 
in 1993 [6, 7, 58].  
 
We compared the cost-effectiveness of periacetabular osteotomy and total hip arthroplasty in 
young adults with developmental dysplasia of the hip. The upper age limit of our population was 
forty-five years, and the time horizon of the model was thirty years. The cost-effectiveness for the 
two procedures is reported from a societal perspective, which accounts for costs and outcomes 
that are important for society rather than for the payer, the physician, or any other single entity 
[59]. Effectiveness and outcome probabilities were obtained from the literature or estimated when 
data were lacking.  
 
The analysis was performed through a decision tree by using a common decision-analysis 
package (TreeAge Pro 2005; TreeAge Software, Williamstown, Massachusetts). An essential 
component of this model was the assumption of a linear annual failure rate for periacetabular 
osteotomy and total hip arthroplasty. A systematic review of the literature and expert opinion 
were used to validate the decision tree [9, 60-71]. We searched PubMed through September 2006 
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for articles using the terms ‘‘periacetabular osteotomy’’ and ‘‘total hip arthroplasty.’’ Inclusion 
criteria were a sample size of greater than twenty-five hips, follow-up of longer than three years, 
mean patient age of forty-five years or less, quantitative outcomes reported as Harris hip scores, 
and outcomes reported by Tonnis grade for periacetabular osteotomy. All data points for total hip 
arthroplasty, except for cost, were taken from the literature. Where data were not available for 
periacetabular osteotomy, we took the most conservative estimate based on the expert opinion of 
two senior orthopaedic surgeons. The model included only objective outcomes. Pain, although 
not directly assessed, was taken into account by use of the Harris hip score. Because several 
periacetabular osteotomy studies have shown a correlation between postoperative success and the 
preoperative radiographic grade of coxarthrosis [65, 70, 72, 73], we ran the model once for each 
Tonnis grade, measuring costs and outcomes for each run. Total hip arthroplasty outcome was the 
same regardless of preoperative radiographic coxarthrosis grade [66]. 
 
Decision Model  
Our decision tree (Fig. 3) consists of two primary treatment arms: periacetabular osteotomy and 
total hip arthroplasty. Branching points thereafter represent complications and terminate in 
outcomes. Outcomes were assigned a quantitative health-related quality of-life value derived 
from the literature. Clinical outcome probabilities, including complications and failure rates, were 
derived from the literature. The total hip arthroplasty arm of the model is similar to past models 
of arthroplasty [9, 74, 75]. The weight of each variable was explored by means of multivariate 
sensitivity analysis.  
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Figure 3: Main decision tree. PAO = periacetabular osteotomy; THA = total hip arthroplasty; 
DDH = developmental dysplasia of the hip; OA = osteoarthritis; HO = heterotopic ossification 
 
Table 6 summarizes the sensitive variables used in the model. Sensitive variables yield 
quantitatively large effects on model outcome and are hence addressed in detail herein. In 
contrast, robust variables are those that, as determined by sensitivity analysis, do not significantly 
affect model outcome. Probability inputs for the model were annual probabilities derived by 
dividing the overall failure rate by the average follow-up time reported in the literature, thereby 
yielding a linear failure rate. For total hip arthroplasty, the complications modeled were aseptic 
and septic failure. Our model represents quality of life after a successful revision total hip 
arthroplasty as being slightly lower than quality of life after a successful primary total hip 
arthroplasty [76, 77]. Similar to a previously validated total hip arthroplasty model, aseptic failure 
included prosthetic wear, loosening, and breakage [9]. The literature reports an annual aseptic 
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failure rate in the range of 1.9% to 3.7% [74, 78-83]. We selected a weighted average of the 
above studies at an annual aseptic failure rate of 2.6%. 
 
Variable Value 
Probability of Primary Aseptic Failure .026 per annum 
Average Lifespan of THA 14 years 
Average Lifespan of PAO 10 years 
Utility of an Excellent Outcome 1.0 
Table 6: Sensitive variables used in the model.  Sensitive variables have a significant effect on 
model outcome.   
 
For periacetabular osteotomy, the complications modeled were periacetabular osteotomy failure 
resulting in conversion to total hip arthroplasty, periacetabular osteotomy revision secondary to 
overcorrection or undercorrection, and heterotopic ossification. Failure rates of periacetabular 
osteotomy were modeled to be different according to Tonnis grade, with rates of 1%, 3%, and 9% 
for Tonnis grades 1, 2, and 3, respectively [70]. The probability of revision was modeled to be 
4% [68], and the probability of heterotopic ossification was 2.4% [70]. Other possible 
complications, such as neural or vascular injury, were so rare [63] and transient that they exerted 
no effect on cost and effectiveness and were thus excluded from the model.  
 
The longevity of total hip arthroplasty varies with respect to the population in which the 
procedure is performed. When it was possible, we used total hip arthroplasty studies that 
described results in an age group similar to that in which periacetabular osteotomy is a treatment 
option. By extracting data from articles that directly report a mean or median survival of total hip 
arthroplasty [80, 82, 84], and by confirming those values by extrapolating median survival 
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through an assumption of a linear failure rate, we found that survival of total hip arthroplasty 
ranges from 6.6 to 25.9 years [74, 78-82]. The value we chose to use, fourteen years, is the 
weighted average of the above trials.  
 
Because of the lack of longer-term follow-up with periacetabular osteotomy, the longevity of the 
procedure is still unknown. In order to determine a survival range for sensitivity analysis, we 
extrapolated the median survival of periacetabular osteotomy by assuming a linear failure rate in 
articles describing follow-up for periacetabular osteotomy beyond four years. The resulting range 
of values for median survival was 8.6 to 19.6 years, while the weighted mean survival was ten 
years [60, 68, 70, 72, 73, 85, 86]. For the best and worst-case scenarios, we used empirical data 
derived from studies describing the survivability of periacetabular osteotomy in hips with more 
than four years of follow-up [71, 72, 85], ranging from 7.1 years in one study [85] to twelve years 
(twenty-two of twenty-six hips) in another [73]. The value chosen for our reference case was ten 
years, and it was based on the weighted mean survival reported above. 
 
Medical Costs 
Cost data (not charge data) were compiled and verified with use of our institution’s activity-based 
costing software (IDX, Burlington, Vermont) that tracked our hospital decision support system. 
Cost data are reported in 2004 U.S. real dollars. The range of values was determined by 
identifying the lowest and highest costs in our patient cohort. Costs for heterotopic ossification 
were estimated, and the impact of estimating that cost was assessed in the sensitivity analysis. 
When we varied the cost of heterotopic ossification from $5000 to $15,000, it changed the 
breakeven points by less than one month, which is negligible over the multiple year time horizon 
of our model. Thus, estimating the cost of heterotopic ossification was not deemed important. 
Costs were discounted at a rate of 5% in order to yield the present monetary value. The time of 
failure of a hip impacted cost— hips that failed earlier incurred potentially more cost in the time 
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course of the model. 
 
Utilities 
We determined effectiveness in terms of health-related quality of life, which was ascertained by 
applying the continuous utility assessment method devised by Hazen et al. [10] and applied to 
total hip arthroplasty by Chang et al. [9]. We mapped health-related quality of- life values to 
Harris hip scores according to the system of Chang et al., and patient utility analyses done before 
and after total hip arthroplasty [56, 67, 87]. Consistent with the outcomes reported in the 
literature, a successful primary periacetabular osteotomy in hips with Tonnis grade-1, 2, and 3 
coxarthrosis had health-related quality-of-life values of 1.0, 0.8, and 0.6, respectively [70]. The 
same health-related quality-of-life value was given to either total hip arthroplasty or 
periacetabular osteotomy, according to the outcome assessed by Harris hip scores, and a 
corresponding adjectival rating was given. In our final analysis, utility values were multiplied by 
the discounted number of years spent in a health state to yield quality adjusted life years 
(QALYs) gained. QALYs were discounted at a rate of 5% to yield present value [6, 8, 12]. As 
with cost, the time of failure of a hip impacted the outcome patients with a hip that failed earlier 
potentially may live longer with a lower health related quality of life. A successful total hip 
arthroplasty subsequent to failure of a periacetabular osteotomy was assigned a good health-
related quality-of-life outcome of 0.8 rather than the excellent outcome of 1.0, associated with a 
primary total hip arthroplasty.  
 
Incremental cost-effectiveness ratios were used to aid comparison of treatments. The incremental 
cost-effectiveness ratio presented in the results is averaged over the thirty-year time horizon of 
the model. The incremental cost-effectiveness ratio is calculated as follows: (CostPAO – 
CostTHA) / (QALYsPAO – QALYsTHA), with PAO indicating periacetabular osteotomy and 
THA indicating total hip arthroplasty. The net health benefit was used as a measure of outcome 
 31 
from a societal perspective because it takes into account the willingness of the health-care system 
to pay (WTP). The net health benefit may be calculated as QALYs – Cost /WTP [88]. The net 
health benefit, while not usually reported in the orthopaedic literature, is used in other specialties 
as it offers the advantage of easy comparison between different treatment strategies. When two 
cost-saving treatments are compared, the better modality has the higher net health benefit, 
whereas it would have the lower incremental cost-effectiveness ratios since incremental cost-
effectiveness ratios can be expressed in negative terms [88-91]. 
 
Sensitivity Analysis 
Sensitivity analysis addressed the uncertainty inherent to drawing data from multiple sources [6]. 
In the case of our model, variables that made a substantial contribution to results were deemed to 
be sensitive, whereas those that contributed <1% to the total outcome were deemed robust. We 
varied sensitive variables according to coxarthrosis, measured radiographically as grade 1, 2, or 3 
according to the method of Tonnis [92].  
 
An expanded sensitivity analysis was conducted on the average duration of Tonnis-grade 1 and 
grade-2 hips after periacetabular osteotomy on the basis of a best-case and a worst case scenario 
for survival. For these two end-point scenarios, we chose the lowest and highest average survival 
rates reported in the literature for periacetabular osteotomy [73, 85]. We did not do this for 
Tonnis grade-3 hips because changing the value of hip survival does not change the results 
substantially. 
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Results 
Cost-effectiveness Analysis of Core Decompression 
Reference Case Results 
A reference case was created that assumed that core decompression delays the need for THA for 
10 years. Given the uncertainty of this assumption, the effects on the cost-effectiveness of core 
decompression of both shorter and longer assumptions for its efficacy are examined in the 
sensitivity analysis.  
 
In the reference case, the pathway of core decompression is assumed to delay hip arthroplasty for 
10 years and resulted in 20.20 QALYs, whereas observation resulted in 19.75 QALYs. This 
represents an incremental gain of 0.45 QALYs when core decompression was chosen over 
observation. Core decompression generated total expected lifetime treatment costs of $27498. 
This results in an incremental increase in cost of $4298 when compared with the lifetime 
treatment costs of $23200 for observation followed by arthroplasty. This led to an incremental 
cost-effectiveness ratio of $9551 for each QALY gained when core decompression was chosen 
over observation. 
 
Sensitivity Analysis 
Effect of Changing the Assumed Length of the Delay in the Need for THA After Core 
Decompression.  
The reference case assumes that core decompression delays hip arthroplasty for 10 years as 
compared with 2 years with observation in the early stages of osteonecrosis. Core decompression 
has not been definitively demonstrated to result in delays of this length. There are conflicting 
reports in the literature, with some authors showing delays of this length and others reporting 
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results below this threshold [18, 93]. Sensitivity analysis was used to evaluate the effects of 
varying the underlying assumption for the success of core decompression on its cost effectiveness 
ratio. The cost effectiveness of core decompression decreases as its assumed ability to delay hip 
arthroplasty decreases. The cost effectiveness ratio rises to more than $25000 per life year as the 
period of delay falls below 7 years. The $50000 cost per life year gained threshold is passed as 
this period falls below 5 years. 
 
Effect of Function After Core Decompression. 
The reference case assumes that successful core decompression prevents painful symptoms 
during the period it is delaying the need for primary arthroplasty. This control of pain is reflected 
in the high utility value of 0.9 assigned to patients during this waiting period. Sensitivity analysis 
was conducted to model clinical situations in which core decompression does not perform well in 
mitigating the functional limitations caused by advancing osteonecrosis. The cost-effectiveness 
ratio of core decompression rises to more than $50000 per QALY gained when the utility during 
the period after the procedure and before conversion to THA is assumed to be lower than 0.86. 
 
Effect of Complication Rate After Core Decompression.  
Subtrochanteric hip fractures complicating core decompression have been reported infrequently, 
although some studies have shown rates as high as 5%. Sensitivity analysis demonstrated that the 
cost-effectiveness ratio rose or fell only slightly over the range of values from 0% to 5%. Even at 
an assumed fracture rate of 5%, the cost-effectiveness ratio of core decompression remained 
lower than $12000 per QALY. 
 
Effect of Complication Rates After Arthroplasty. 
The rates of complications after THA have been reported by several authors [31, 33-37]. The 
assumed durability of hip arthroplasty and incidence of complications including death, 
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dislocation, and infection were selected to be in the midrange of accepted values. Sensitivity 
analysis was used to examine the impact of using high- and low-range values for these variables. 
As the assumed complication rates after hip arthroplasty decrease, core decompression becomes a 
less cost-effective treatment option. This occurs because some of the cost-effectiveness gains 
from core decompression result from the delay or avoidance of the costs and negative health 
impacts that result from these complications. However, these effects were not large and did not 
alter the conclusions of this study. Even under conditions in which the complication rates of THA 
are assumed to be negligible, core decompression remained highly cost-effective with an 
incremental cost effectiveness ratio lower than $13000 per QALY gained. 
 
Effect of Discount Rate.  
Analyses assuming discount rates of 0% and 5% in addition to the baseline assumption of 3% 
were conducted. These variations in the discount rate did not have a large impact on the cost-
effectiveness ratios. A discount rate of 0% led to an incremental cost effectiveness ratio for core 
decompression of $12429 per QALY gained. A discount rate of 5% resulted in a ratio of $9620 
per QALY gained. These ratios fall well below the threshold of $50000 per QALY commonly 
used to judge procedures as moderately cost-effective [6]. 
 
Cost-Effectiveness Analysis of Unicompartmental Knee 
Arthroplasty as an Alternative to Total Knee Arthroplasty for 
Unicompartmental Osteoarthritis 
Reference Case Results 
A reference case was created with use of the assumption that unicompartmental arthroplasty 
results in a high level of function for twelve years. The assumption of twelve years of function is 
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consistent with that in published clinical series, but there are limited data available that directly 
compare the durability of unicompartmental knee replacement and total knee replacement [44-
53]. Given the uncertainty of this assumption, the impact on the cost-effectiveness of 
unicompartmental arthroplasty of both shorter and longer assumptions for its effectiveness is 
examined in the sensitivity analysis.  
 
In the reference case, the pathway of unicompartmental knee arthroplasty resulted in a small gain 
in effectiveness to 12.21 quality-adjusted life years compared with 12.19 quality adjusted life 
years when total knee arthroplasty is chosen. There was minimal change in costs, with an increase 
from $18,995 to $19,000 (in 1998 United States dollars). The incremental cost-effectiveness ratio 
for unicompartmental knee arthroplasty under the reference case assumption is negligible with a 
cost of $277 per quality-adjusted life year gained. This ratio indicates that unicompartmental knee 
arthroplasty was more effective than total knee arthroplasty, and this increased effectiveness 
required a minimal additional cost. 
 
Sensitivity Analysis 
Effect of the Durability of Unicompartmental Knee Replacement Compared with Total Knee 
Replacement 
The durability of unicompartmental knee replacements remains uncertain relative to total knee 
replacements. Sensitivity analysis was used to evaluate the effects of this uncertainty by varying 
the underlying assumption for the durability of unicompartmental knee replacements and 
determining the changes to the cost-effectiveness ratio. The cost effectiveness of 
unicompartmental knee arthroplasty is lost as the durability of the implant is assumed to decrease. 
The reference case assumes a survival of fifteen years for primary total knee replacement. The 
assumption of a longer survival for total knee replacement compared with unicompartmental knee 
replacement reflects the longer experience and more complete documentation of the durability of 
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total knee replacement. The cost-effectiveness of unicompartmental knee arthroplasty relies 
largely on its ability to produce clinical results approaching those of total knee arthroplasty. In 
sensitivity analyses that assume unicompartmental knee replacement has a survival of eleven 
years, it becomes both less effective (12.16 compared with 12.19 quality-adjusted life years) and 
more costly than standard total knee arthroplasty ($19,233 compared with $18,995). This scenario 
results in total knee arthroplasty becoming a dominant choice. Specifically, total knee 
arthroplasty becomes both more effective and less costly when unicompartmental knee 
replacement is assumed to have a survival below the threshold of eleven years (Table 7).  
 
Values Used in Sensitivity Analysis Incremental Cost of 
Unicompartmental 
Compared with Total 
Knee Arthroplasty 
Incremental Effectiveness 
of Unicompartmental 
Compared with Total Knee 
Arthroplasty (QALY) 
Incremental Cost-
Effectiveness Ratio of 
Unicompartmental Compared 
with Total Knee Arthroplasty 
(Cost/QALY) 
Reference case 
Unicompartmental knee 
replacement survival assumed to 
be 12 yr. 
Total knee replacement survival 
assumed to be 15 yr. 
+$5  +0.02  $277 
   
   
Scenario 1 
Unicompartmental knee 
replacement survival assumed to 
be 11 yr. 
Total knee replacement survival 
assumed to be 15 yr. 
+$238   0.03   TKA is dominant  
   
   
Scenario 2 
Unicompartmental knee 
replacement survival assumed to 
be 17 yr. 
Total knee replacement survival 
assumed to be 20 yr. 
+$6,236  +0.13  $45,958 
   
   
Scenario 3  
Unicompartmental knee 
replacement survival assumed to 
be 15 yr. 
Total knee replacement survival 
assumed to be 20 yr. 
+$6,859  +0.05  $117,103 
   
   
Cost of unicompartmental knee 
arthroplasty increased by 25%  
+$2,661  +0.02  $165,354 
Cost of unicompartmental knee 
arthroplasty decreased by 25% 
-$2,652 +0.02 Unicompartmental knee 
replacement is dominant 
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Table 7: Incremental Costs, Effectiveness, and Cost-Effectiveness Ratios with Use of Reference 
Case and Sensitivity Analyses 
 
 
 
 
Multivariate sensitivity analysis was also performed with use of a broader range of fifteen to 
twenty years for the expected durability of total knee replacement. These analyses indicated that 
it is necessary for the assumed survival of the unicompartmental knee replacement to be within 
three to four years of the assumed survival of the total knee replacement in order to maintain the 
cost-effectiveness of choosing unicompartmental knee arthroplasty. This is demonstrated by 
analyses that assume that total knee replacement survival is twenty years. With use of this 
assumption, the incremental cost-effectiveness ratio of unicompartmental knee arthroplasty is 
$45,958 per quality-adjusted life-year gained compared with total knee arthroplasty when a 
unicompartmental knee replacement is assumed to survive for seventeen years. This is below the 
commonly accepted threshold of $50,000 per quality-adjusted life year often used to determine 
cost effective procedures [6, 9]. In contrast, when the survival of a unicompartmental knee 
replacement is assumed to be fifteen years and the survival of a total knee replacement is assumed 
to be twenty years, the incremental cost-effectiveness ratio increases to more than $100,000 per 
quality-adjusted life-year gained (Table 7). The incremental cost effectiveness ratio continues to 
increase, and the cost-effectiveness of unicompartmental knee arthroplasty decreases as the 
survival of a unicompartmental knee replacement is assumed to be lower relative to the survival 
of a total knee replacement. 
 
Effect of Function Following Unicompartmental Knee Arthroplasty 
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The initial published findings indicate that unicompartmental knee arthroplasty results in function 
that is at least comparable with that seen after total knee arthroplasty [44, 46-52, 94]. The 
reference case reflects these results by assuming that both unicompartmental knee arthroplasty 
and total knee arthroplasty result in a high level of function and pain relief. However, there are a 
limited number of controlled studies that have directly compared the clinical function after 
unicompartmental knee arthroplasty and total knee arthroplasty. This uncertainty was addressed 
in a sensitivity analysis that examined the effect of higher and lower values for the utility of 
unicompartmental knee arthroplasty on its cost effectiveness.  
 
The reference case results show a small gain of 0.02 quality-adjusted life years when 
unicompartmental knee arthroplasty is chosen over total knee arthroplasty. These gains are lost 
when the utility of unicompartmental knee arthroplasty is assumed to be less than that of total 
knee arthroplasty. Conversely, there is a further incremental increase in the cost-effectiveness 
when the utility of unicompartmental knee arthroplasty is assumed to be >0.9. When 
unicompartmental knee arthroplasty is assigned the maximal value of 1.0, it results in a total of 
13.20 quality-adjusted life years as opposed to 12.19 quality-adjusted life years for a gain of 1.01 
quality-adjusted life years. Unicompartmental knee arthroplasty becomes a more cost-effective 
choice under these assumptions, as the gains in incremental effectiveness increase with no 
additional cost relative to the reference case. 
 
Effect of Cost of Unicompartmental Knee Arthroplasty 
There is a small incremental additional cost from unicompartmental knee arthroplasty with use of 
the reference case assumptions for the relative costs of unicompartmental and total knee 
arthroplasty. The minimal cost increase in the reference case results from the assumption that 
there is a decrease in the physician’s fee for unicompartmental knee arthroplasty relative to the 
fee reimbursement for total knee arthroplasty. Unicompartmental knee arthroplasty becomes a 
 39 
less cost-effective alternative in a sensitivity analysis in which the cost of unicompartmental knee 
arthroplasty is assumed to be higher than the cost of total knee arthroplasty. An increase of 25% 
resulted in an incremental cost-effectiveness ratio of $165,354 per quality adjusted life year 
gained when unicompartmental knee arthroplasty was chosen over total knee arthroplasty. This 
indicates that the cost-effectiveness of unicompartmental knee arthroplasty may be lost if it 
requires a large relative increase in cost compared with total knee arthroplasty (Table 7 above).  
 
The use of gross costing based on Medicare reimbursement does not account for the potential 
savings of unicompartmental knee arthroplasty from implant costs or decreased hospital length of 
stay. This is due to the fact that both unicompartmental knee arthroplasty and primary total knee 
arthroplasty are assigned the same DRG, resulting in a similar cost assumption for the hospital 
stay. A sensitivity analysis was performed to examine the effect of a 25% cost-savings in a 
comparison of unicompartmental knee arthroplasty with total knee arthroplasty. A decrease of 
25% in the assumed costs of unicompartmental knee arthroplasty resulted in an overall savings of 
$2652 in the lifetime treatment costs compared with those of primary total knee arthroplasty 
(Table 7 above). 
 
Cost-Effectiveness Analysis of Periacetabular Osteotomy 
Cost 
Costs were averaged over the thirty-year time horizon of the model. The average cost of total hip 
arthroplasty in all three Tonnis grades of coxarthrosis was $32,790. In Tonnis grade-1 and grade-
2 hips, periacetabular osteotomy yielded a cost of $26,592 and $30,673, respectively. The cost of 
periacetabular osteotomy in Tonnis grades 1 and 2 was cost-saving compared with total hip 
arthroplasty, i.e., it was below the abscissa in Figure 4. Periacetabular osteotomy in Tonnis grade 
3 was associated with a cost of $33,465, which resulted in an incremental cost (above the abscissa 
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in Figure 4) of $675. 
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Figure 4.  Average incremental costs and incremental quality-adjusted life years for peri-
acetabular osteotomy (PAO) compared with total hip arthroplasty (THA). 
 
Effectiveness 
QALYs gained were averaged over the thirty-year time horizon of the model. In each of the three 
Tonnis grades of coxarthrosis, total hip arthroplasty resulted in an average of 4.7QALYs gained. 
Periacetabular osteotomy in Tonnis grade-1, 2, and 3 hips yielded an average of 4.85, 3.3, and 3.2 
QALYs gained, respectively. Compared with the QALYs gained with total hip arthroplasty, the 
increment in QALYs gained with periacetabular osteotomy in Tonnis grade-1 coxarthrosis was 
0.15 (represented in Figure 4 by the data point for Tonnis grade-1 hips lying to the right of the 
ordinate). In addition, for Tonnis grade-2 and grade-3 hips, total hip arthroplasty yielded, on the 
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average, more QALYs (both data points lie to the left of the ordinate) than did periacetabular 
osteotomy (Fig. 4).While over thirty years, total hip arthroplasty is more effective (i.e., it yields 
more QALYs) on the average than periacetabular osteotomy in Tonnis grade-2 coxarthrosis, 
periacetabular osteotomy becomes the more effective treatment by year 19.4 of the model. For 
Tonnis grade-3 coxarthrosis, total hip arthroplasty is and remains more effective throughout the 
time period of the model. 
 
Cost-Effectiveness and Incremental Cost-Effectiveness 
Cost-effectiveness ratios were averaged over the thirty-year time horizon of our model. The cost-
effectiveness ratio of total hip arthroplasty was $11,631/QALY for all three Tonnis grades. In 
Tonnis grade-1, 2, and 3 coxarthrosis, periacetabular osteotomy had a cost-effectiveness ratio of 
$7856/QALY, $10,807/ QALY, and $15,005/QALY, respectively. Since periacetabular 
osteotomy in Tonnis grade-1 coxarthrosis is, on the average, both more effective than total hip 
arthroplasty and more cost-saving (lower right quadrant in Figure 4), it is the dominant procedure 
in this setting. For Tonnis grade-1 coxarthrosis, periacetabular osteotomy is more cost-effective 
over thirty years and surpasses total hip arthroplasty in cost-effectiveness at 5.5 years. In Tonnis 
grade-2 coxarthrosis, periacetabular osteotomy is less costly than total hip arthroplasty on the 
average but also less effective (lower left quadrant in Figure 4). While both incremental cost and 
effectiveness are negative for periacetabular osteotomy in Tonnis grade-2 coxarthrosis, the former 
effect is greater than the latter effect, making periacetabular osteotomy ultimately more cost-
effective than total hip arthroplasty in this grade, with an associated incremental cost-
effectiveness ratio of –$824/QALY. For Tonnis grade-2 coxarthrosis, periacetabular osteotomy is 
more cost-effective over thirty years and surpasses total hip arthroplasty in cost-effectiveness at 
18.25 years. Periacetabular osteotomy was both more costly and less effective on the average than 
total hip arthroplasty in Tonnis grade-3 coxarthrosis (upper left quadrant in Figure 4); as a result, 
total hip arthroplasty is the dominant procedure in this setting. 
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Net Health Benefits 
Figures 5 and 6 depict the results for the two treatments in terms of net health benefits. In Tonnis 
grade-1 coxarthrosis (Fig. 5), periacetabular osteotomy yields a greater net health benefit after 
10.1 years in comparison with total hip arthroplasty. In Tonnis grade-2 coxarthrosis (Fig. 6), 
periacetabular osteotomy reaches equivalence by 19.1 years, after which it becomes dominant. If 
periacetabular osteotomy can be expected to have a greater longevity than the crossover points of 
10.1 years and 19.1 years for Tonnis grade 1 and 2, respectively, then periacetabular osteotomy as 
a treatment would be preferable to total hip arthroplasty in terms of net health benefits. Finally, at 
no point does periacetabular osteotomy yield a negative net health benefit in both Tonnis grades 1 
and 2, whereas total hip arthroplasty does so at 23.5 years and 25.1 years, respectively. These 
results are summarized in Table 8, which shows how long (in years) a periacetabular osteotomy 
must survive to become the preferred treatment modality. 
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Figure 5. Tönnis 1 Incremental Net Health Benefits $/QALY's (WTP = $50,000). 
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Figure 6. Tonnis 2 Incremental Net Health Benefits $/QALY's (WTP = $50,000). 
 
  Effectiveness Cost Cost Effectiveness NHB 
Survival of PAO 
needed to be 
preferred 
treatment (years) 
Tönnis 
grade 1 
10.8 PAO always 
preferred 
5.5 10.1 
Tönnis 
grade 2 
19.4 PAO always 
preferred 
18.25 19.1 
Tönnis 
grade 3 
THA always 
preferred 
THA always 
preferred 
THA always preferred THA always 
preferred 
Table 8. The number of years PAO needs to survive for it to be a preferred treatment over THA, 
given assessment by either Effectiveness, Cost, Cost-Effectiveness or NHB (Net Health Benefits). 
 
Sensitivity Analysis 
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We performed a multivariate sensitivity analysis for each Tonnis grade. Multivariate analysis 
identified five consistently sensitive variables for Tonnis grades 1 and 2 that contributed >99% of 
the total variability in outcome: (1) average lifespan of the periacetabular osteotomy, (2) 
probability of a failed periacetabular osteotomy, (3) average lifespan of a total hip arthroplasty, 
(4) probability of an aseptic revision, and (5) utility of excellent outcome.  
 
We summarize the results of our worst and best-case analyses in Table 9. The cost-effectiveness 
and effectiveness of periacetabular osteotomy improved considerably as the functional life of the 
Tonnis grade-1 hip after periacetabular osteotomy increased. In the worst-case scenario, 
periacetabular osteotomy is, on the average, more cost-effective than total hip arthroplasty and 
reaches equivalence at 11.45 years for Tonnis grade-1 coxarthrosis. In the worst-case scenario for 
Tonnis grade-2 coxarthrosis, periacetabular osteotomy, while it is not more cost-effective, on the 
average, than total hip arthroplasty, reaches equivalence at 18.6 years. The range of reaching 
equivalence is broader from best-case to worst-case scenarios for Tonnis grade-1 compared with 
Tonnis grade-2 coxarthrosis because periacetabular osteotomy survival is not as sensitive a 
variable for the latter. For both Tonnis grade-1 and grade-2 hips, periacetabular osteotomy always 
remained below $50,000 per QALY gained for all of the values we tested in our sensitivity 
analysis. 
 
 Tönnis grade 1 Tönnis grade 2 
 Avg CE ($/QALY) : 
EV time (years) 
Avg E (QALYs) : 
EV time (years) 
Avg CE ($/QALY) : 
EV time (years) 
Avg E (QALYs) : EV 
time (years) 
Worst case 
scenario  
- 5689 : 11.45 -1.1 : 16.35 200 : 18.6  -1.9 : 19.8  
Reference -7856 : 5.5 .15 : 10.8 - 824: 18.25 - 1.4 : 19.4 
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case 
Best case 
scenario 
- 8800 : 2.45 1.0 : 5.9 - 1152 : 17.8  -1.1 : 19.2 
 
Table 9. Sensitivity analysis based on worst case and best case durability of a PAO hip showing 
average incremental cost-effectiveness (Avg CE), average incremental effectiveness (Avg E), the 
time point where equivalence between PAO and THA is attained (EV time) in terms of cost-
effectiveness and effectiveness, and the peak effectiveness of PAO in terms of maximum potential 
gain in QALYs over the time span of our model.   
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Discussion 
With each passing year, healthcare costs consume an ever increasing percentage of our Gross 
Domestic Product (GDP) [95]. Disease burden in the US is no greater than in peer countries of 
the Organization for Economic Co-operation and Development (OECD), but our input costs are 
intrinsically more expensive [96]. Unfortunately, we are getting a bad deal for this high price, at 
least by the metrics we claim to be important. Within the group of OECD countries, the US has 
among the highest infant mortality rates, the lowest life expectancies, and the greatest level of 
obesity [97]. We pay a premium cost for an inferior result. 
 
One possible reason for this combination is our reimbursement structure. Before 1982, the 
government reimbursed physicians according to the cost of a procedure. Resource intensive 
procedures predictably acquired favor. Diagnostic related groups (DRGs) were instituted to 
address the perverse incentive of trying to use more resources in order to increase 
reimbursements. The new incentive created by DRGs, however, was to spend less time per 
procedure in order to perform as many procedures as possible. We still do not know with precise 
statistics how this dynamic has affected outcomes in medical practice.  
 
Most recently, there have been attempts to link reimbursement to outcome metrics, such as 
quality or efficiency [98]. There are several potential requirements to make a value-based 
reimbursement structure that focuses first and foremost on patient welfare while still accounting 
for resource constraints. Two of the most prominent requirements are unambiguous measures of 
quality and accurate measurements of cost. Within the realm of orthopaedic surgery, this thesis 
presented 3 articles that compared quality and cost for alternative treatments.  
 
Defining costs 
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Costs can be direct or indirect, as was discussed in the introduction. In terms of cost effectiveness 
analysis, this is usually where researchers end their measurements. That is a mistake. 
Considerations of other types of cost are crucial, in particular fixed cost, variable cost, average 
total cost, and marginal cost. 
 
Fixed cost is defined as a cost that does not vary with usage. The cost of an operating room table 
is an example. The hospital buys the table and installs it. The cost of doing so remains the same 
no matter how many times it is used. Fixed costs can change over the long term, however, 
especially if the product depreciates. The operating table may require, for example, more 
maintenance as it gets older. A subset of fixed costs that cannot change over the long term is sunk 
costs. These costs occur when an item with a fixed cost cannot be used for any other purpose in 
the short term or long term. An old operating table might be used for instructional purposes in 
another setting, but the operating suite itself has only one purpose. The former is a regular fixed 
cost; the latter is a sunk cost. 
 
Variable costs change according to the amount of output being produced. The salaries of scrub 
nurses paid on a per time basis are examples of variable costs, as they increase with both longer 
surgeries and with the number of surgeries performed. The amount of gloves and towels used for 
a surgery constitute another example. Total costs equal fixed costs plus variable costs.  
 
Average total cost is simply the total cost divided by the quantity produced. Marginal costs are 
the cost of producing one extra unit. Marginal cost differs from average total cost when the 
production of an extra unit raises or lowers the variable cost. In the corporate world the difference 
between the two is obvious. When workers in a car factory make their first car, they become more 
proficient at their job. Production of their second car is therefore done more rapidly and with 
fewer mistakes (i.e., variable cost goes down). Production of their third car improves as well, 
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although data show that the rate of improvement decreases – that is, there is a negative second 
derivative that represents diminishing returns. This means that marginal cost is less with each 
subsequent car, up to a certain plateau.  
 
Perhaps the same applies to the learning curve of a surgeon for a new procedure. The state of 
surgery research, however, is that none of this has been studied. From an economics perspective, 
we do not have good data on marginal costs in the healthcare environment. This is acceptable 
when deciding whether to apply a new intervention to a population that is receiving no 
intervention at all. In that case average total costs can be used. It is a problem in cases such as the 
articles in this thesis, in which one compares a newer procedure to a more established procedure. 
Marginal cost is a more sensible approach for comparing competing procedures [99, 100].  
 
Interpreting results 
The driving reason for doing a cost effectiveness analysis is ambiguity. If a newer intervention 
were both more effective and less costly, it would be adopted without hesitation – indeed, without 
analysis. Analysis is necessary for two reasons: 1. Cases in which the effectiveness and cost of 
the newer intervention are not known with accuracy; and 2. Cases in which the newer 
intervention is superior in just one category, typically in being more effective, but inferior in the 
other category, typically in being more costly.  
 
For the first reason, cost effectiveness analysis is done to give a range of values that a doctor can 
use in his practice. This was the case for the knee arthroplasty article in this thesis. The costs of 
the procedures were not easily available to the researchers, especially the indirect costs as usually 
represented in hospital accounting software. We were compelled to use DRG charge data and 
validate these data with costs from the literature. Additionally, the outcome of the newer 
procedure, the unicompartmental knee arthroplasty, was not known with any statistical power. 
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We therefore conducted a sensitivity analysis with several scenarios to explore how long the 
unicompartmental knee arthroplasty would need to last before revision in order to be as cost 
effective as a total knee arthroplasty. The take-home message for an orthopaedic surgeon is that a 
UKA does not need to last as long as a TKA to be as cost effective. It could last 3 - 4 years less, 
and this difference held whether the duration of the TKA were 20 years, 15 years, or some value 
in between. The experienced orthopaedic surgeon could assess how long his total knees last and 
prognosticate accordingly.  
 
The PAO article illustrates both cases. There is an ambiguity about the effectiveness of PAO, and 
PAO may be superior in only one category, cost or effectiveness. Data on the outcomes of PAO 
are scarce. This was one of the motivations for conducting research on it. We wanted to 
understand, at a minimum, how long a PAO must last in order for it to be a worthwhile procedure 
compared to THA. The answer to this question happened to differ according to Tonnis grade. For 
it to be worthwhile just in terms of effectiveness in Tonnis grade 1, it needed to last 10.8 years. 
For it to be worthwhile just in terms of effectiveness in Tonnis grade 2, it needed to last 19.4 
years. In Tonnis grade 3 it was never more effective, and when cost was factored in, these 
numbers changed. PAO was found to be less costly in Tonnis grades 1 and 2 and more costly in 
Tonnis grade 3. For example, when factoring in cost and effectiveness for Tonnis grade 1, a PAO 
needed to last only 5.5 years to be the preferred choice. In Tonnis grade 2 it needed to last 18.25 
years to be preferred.  
 
By reporting the results in this manner, we gave the orthopaedic surgeon the option to use them as 
he wishes. If money were no object, it would mean that the surgeon would use only the duration 
thresholds for effectiveness. In resource-limited environments, by contrast, the duration threshold 
for cost-effectiveness could be considered.  
 
 51 
This approach also demonstrates the situation in which PAO may be better in only certain 
settings. Specifically, PAO was found to be much less costly on average in Tonnis grade 1. It was 
also found to be slightly more effective. If one believes that these assertions are well founded, the 
decision to use PAO is automatic. In this setting PAO is the dominant choice. Similarly, in 
Tonnis grade 3 PAO is both more costly and less effective. If one believes that these particular 
assertions are well founded, one must conclude that THA in this setting is dominant. Beyond the 
usefulness of quantifying these issues and analyzing them in a transparent structure, cost 
effectiveness analysis is a worthy exercise in the middle scenario. For PAO, this was Tonnis 
grade 2, where PAO is less costly than THA but on average is also less effective. This grey zone 
is where the orthopaedic surgeon will seek out data to make a judgment. In the absence of data, a 
model such as ours can be used, which is precisely what was represented in Figure 4 in the results 
section for PAO.  
 
Limitations of cost effectiveness 
Perhaps one of the greatest limitations of this kind of research comes from the state of research in 
orthopaedic surgery. There is such a shortage of well-conducted, large randomized trials in 
orthopaedics that the data sources for the models are limited. Even the most well constructed 
model has little value when its inputs are of low quality. The gold standard for assessing clinical 
benefits is the randomized controlled trial. In the case of many orthopaedic procedures, and 
certainly in the case of the ones assessed in this thesis, this is not easily feasible. Such trials 
would take years to complete and would have prohibitive costs. By the time they were completed, 
the technology of the field would have evolved to a new stage.  
 
Large registries are an acceptable alternative, such as the nationwide hip registry in Sweden. 
Indeed, much of my THA data comes from that registry. Whether or not such a registry is 
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possible in a country without a national healthcare system, such as the US, is still an open 
question. 
 
Another problem with assessing cost and effectiveness in medicine in general is that the best way 
to do so would be to integrate these factors into the very methodology of every prospective 
clinical trial. Tracking resource use and assessing outcomes should in fact be done simultaneously 
in order to understand specific links between which resources lead to which outcomes. 
Unfortunately, the data points required to achieve statistical significance for economics variables 
are much greater than those needed for clinical variables. The addition of economic analysis to a 
clinical trial is therefore highly likely to make the trial underpowered [100, 101].  
 
Given this situation, we face a problem of “garbage in, garbage out.” The only time the issue can 
be avoided is when the older technology has an established abundance of data, such as with THA. 
In that case we can use sensitivity analysis on the newer technology to assess when and how it 
can be useful. As pointed out, this approach was used in the analysis of PAO and THA. 
 
There is also a concern with the methodology of cost effectiveness analysis. QALYs are by 
definition subjective measurements of value. They depend on individual preferences, translated 
into utilities, and these individual preferences are then applied to the general public. There may 
be huge variations for any given patient on how they value an extra year of life with, for example, 
the ability to walk free of pain [102, 103]. Furthermore, differences in these preferences may vary 
dramatically across cultures as well as within professions that have greater physical demands 
[104]. There is also the considerable ethical problem that QALYs by definition will be less for 
older patients with fewer remaining years of life and for patients with co-morbidities that 
guarantee a lower baseline utility. All of these issues highlight that cost effectiveness is a relative 
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measure. It should be used to enhance clinical judgment with the comparative thresholds and 
benchmarks it can produce. Absolute statements of cost effectiveness are not useful.  
 
Cost effectiveness analysis can also be used to advance the state of research. Models allow us to 
estimate, for example, an adequate population size needed to conduct a randomized trial. They 
would also inform us how much time would be required for completion. These models can help 
identify which variables (i.e., duration of the implant, complication rates, patient characteristics) 
are most influential in determining the total cost effectiveness of the procedure. A doctor can then 
pay particular attention to these in the decision process. A researcher can use these to target 
fruitful areas of inquiry [105], and in fact the model itself may prove simply that no conclusions 
can be drawn until more powerful data are gathered on sensitive variables. Finally, cost 
effectiveness helps us determine whether the information in the literature is specific enough. If in 
fact it is too general, then it serves as a warning to the researcher or surgeon that patients should 
be subdivided depending on characteristics. For PAO versus THA, for example, this could mean 
subdivision of THA into several categories of implants, such as ceramic on ceramic, metal on 
metal, and ultra-high molecular weight polyethylene. 
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Appendix A – Definition of Cost Utility Analysis 
Each article contained the term cost effectiveness in it, but this term is a misnomer. A cost 
effectiveness analysis, in the strict sense, measures health outcomes in units that are specific to 
the two procedures under comparison. For example, a fractured femur could potentially be fixed 
by external fixation or by internal fixation. One common outcome shared by these two methods is 
the rate of nonunion. The cost of each procedure would be compared with nonunion rates in a 
cost effectiveness analysis. In essence a cost effectiveness analysis uses an outcome that is 
deemed important by the doctor. 
 
By contrast, a cost utility analysis uses units that are standardized to all potential procedures, and 
the unit of outcome takes into account the preferences of the patient. The current consensus for a 
standardized unit is the quality adjusted life year (QALY), which equals the number of extra 
years of life, or in the typical case for orthopaedics, extra years of function, multiplied by the 
utility of those years for the patient. While utility assessment can be difficult, there are methods 
for its calculation. One example is the Rosser Index Matrix, which determines patient utility on a 
scale of 0 to 1 by comparing disability ratings of orthopaedics patients to the self-reported distress 
of the patient [106]. Once these standardized utilities are obtained, a cost utility analysis can be 
performed, as was done in the articles here.  
 
Nonetheless, convention favors the use of cost effectiveness to mean cost utility. For the sake of 
ease, I follow this convention.  
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Appendix B – Literature Review for Core Decompression 
 
A.1. Summary of Literature Search 
 
A.1.1 Search Strategy 
Keywords (in permutation) Osteonecrosis, decompression, hip, outcome 
Dates 1978-2004 
Total articles 269 
Articles not relevant 191 
Relevant articles analyzed 78 
Excluded reviews 15 
Excluded articles <50 subjects 30 
Excluded articles that failed criteria 22 
Articles remaining from 78 11 
 
 
A.1.2. Randomized Control Trial Used for Core Decompression and Conservative Treatment 
A.1.2.1. Randomized control trial, more than 50 subjects 
 
• Ref [30] 
A.1.3. Articles Used for Core Decompression 
A.1.3.1. Prospective, more than 50 subjects  
 
• Refs [22, 24-26, 28, 29]. 
A.1.3.2. Retrospective, more than 50 subjects 
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• Refs [23, 27]. 
A.1.4. Articles Used for Conservative Treatment 
 
• Refs [20, 21]. 
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